Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results

BACKGROUND: Boosted protease inhibitor regimens (bPIs) are effective and often used in HIV-infected individuals with difficulties with adherence, but they can have drug–drug interactions and GI adverse effects. Bictegravir (B), a novel, potent integrase strand transfer inhibitor with a high barrier...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Forum Infect Dis
Hauptverfasser: Daar, Eric, DeJesus, Edwin, Ruane, Peter, Crofoot, Gordon, Oguchi, Godson, Creticos, Catherine, Rockstroh, Jurgen K, Molina, Jean-Michel, Koenig, Ellen, Liu, Ya-Pei, Andreatta, Kristen, Graham, Hiba, Cheng, Andrew, Martin, Hal, Quirk, Erin
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2017
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630722/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx180.003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge